Medicare’s Coverage of New Controversial and Expensive Alzheimer’s Drug Is Limited
Medicare will restrict coverage of the controversial and costly Alzheimer’s drug Aduhelm to those enrolled in qualifying clinical trials, the Centers for Medicare and Medicaid Services announced Thursday.